S
Saoirse E. O'Sullivan
Researcher at University of Nottingham
Publications - 96
Citations - 5203
Saoirse E. O'Sullivan is an academic researcher from University of Nottingham. The author has contributed to research in topics: Cannabinoid & Cannabinoid receptor. The author has an hindex of 36, co-authored 92 publications receiving 3914 citations. Previous affiliations of Saoirse E. O'Sullivan include Royal Derby Hospital & University of Limerick.
Papers
More filters
Journal ArticleDOI
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
TL;DR: This review will summarize the published literature implicating cannabinoid‐mediated PPAR effects and discuss the implications thereof.
Journal ArticleDOI
An update on PPAR activation by cannabinoids.
TL;DR: The aims of this review are to update the evidence supporting PPAR activation by cannabinoids and to review the physiological responses to cannabinoids that are mediated, and not mediated, by PPARactivation.
Journal ArticleDOI
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.
TL;DR: The paucity in data and some discrepancy in the pharmacokinetics of cannabidiol are highlighted, despite its widespread use in humans, and robust data from a variety of formulations is required.
Journal ArticleDOI
Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease
TL;DR: There is a convergence of effects of cannabinoids, acting via cell surface and nuclear receptors, on immune cell function which provides promise for the targeted therapy of a variety of immune, particularly neuroinflammatory, diseases.
Journal ArticleDOI
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Khalid A. Jadoon,Stuart H Ratcliffe,David A. Barrett,E. Louise Thomas,Colin Stott,Jimmy D. Bell,Saoirse E. O'Sullivan,Garry D. Tan +7 more
TL;DR: CBD and THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes and were well tolerated.